Trials / Completed
CompletedNCT02958527
Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)
DRUG USE INVESTIGATION OF EFFEXOR(REGISTERED) SR CAPSULES
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,408 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE
Detailed description
This study will be conducted under the central registration system until the number of subjects who meet the conditions for registration reaches the target number of subjects. 12 weeks from the start date. The patients who completed the 12-week treatment with this product will be observed up until Week 52.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | venlafaxine | The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week. |
Timeline
- Start date
- 2016-10-03
- Primary completion
- 2020-05-11
- Completion
- 2020-05-11
- First posted
- 2016-11-08
- Last updated
- 2023-05-22
- Results posted
- 2021-05-24
Source: ClinicalTrials.gov record NCT02958527. Inclusion in this directory is not an endorsement.